Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
13 May 2024 - 10:30AM
Hummingbird Bioscience, a precision biotherapeutics company
discovering and developing transformative biologics for
hard-to-treat diseases, today announced two presentations at the
20th Annual PEGS Boston summit being held from May 13-17, 2024.
Data from the first presentation demonstrates the ability to direct
antibodies and antibody-drug conjugates (ADCs) to rationally
selected epitopes of interest on challenging disease-associated
proteins. Data from the second presentation show how a novel
dual-payload ADC approach has the potential to address resistance
and improve the therapeutic window of ADCs.
“The data presented at PEGS show for the first time how our
proprietary fourth generation antibody-drug conjugate (ADC)
platform leverages novel linker and dual-payload technologies to
overcome the resistance observed with earlier generation single
payload ADCs. Our ADC technology has the potential to treat a large
number of patients that have either intrinsic or acquired
resistance to currently approved ADCs,” said Jerome Boyd-Kirkup,
Ph.D., Chief Scientific Officer, Hummingbird Bioscience. “We will
also showcase how our proprietary Rational Antibody Discovery
platform engineers immune responses in transgenic mice models so
that resulting ADCs and antibodies bind to the key epitopes on
disease-associated proteins for optimal drug properties. These data
continue to support our belief that our next-generation ADC
platform can generate best-in-class ADCs that address payload
resistance, optimize tumor specificity, and enhance payload
delivery, and therefore maximize the anti-tumor potential of
ADCs.”
Presentation details:
Title: Engineering
Immune Responses for Epitope-Focused Antibody
DiscoveryPresenter: Jerome Boyd-Kirkup, Ph.D.,
Chief Scientific OfficerSession: Display of
Biologics - Novel PlatformsDate/Time: Monday, May
13, 2024, 1:45 p.m. ET
Title: Overcoming
Payload Resistance with Dual-Payload
ADCsPresenter: Ben Ayers, DPhil, Vice President,
Antibody-Drug ConjugatesSession: Driving Clinical
Success in Antibody Drug Conjugates - Novel payloads and
MOAsDate/Time: Friday, May 17, 2024, 9:30 a.m.
ET
About Hummingbird Bioscience’s ADC Platform
The 4th generation ADC platform developed by Hummingbird
Bioscience aims to address the key limitations in efficacy and
safety of current approved ADCs. The ADC platform combines the
company’s AI-enabled Rational Antibody Discovery Platform and
proprietary linker and dual-payload technologies to unlock the
power of dual-payload approaches against the most important
disease-associated proteins. The platform engineers potentially
best-in-class ADCs that address payload resistance, optimize
payload delivery and tumor specificity, and maximize anti-tumor
cytotoxic potential.
About Hummingbird Bioscience’s Rational Antibody
Discovery Platform
The Rational Antibody Discovery (RAD) platform is designed to
address the challenges of traditional antibody approaches. This
technology enables the company to identify critical functional
regions of a target protein using mAbPredict, a machine
learning-enabled technology platform that identifies optimal
regions to target, and then drives production of antibodies against
these epitopes using mAbHits, a proprietary immuno-engineering
technology that directs the antibody response to pre-determined
epitopes of interest in the proprietary transgenic HMBD Abvantage
mouse. Unlike classical approaches to antibody discovery that have
limited control over antibody binding regions, and hence, ability
to target optimal epitopes, mAbHits ensures in vivo generation and
affinity maturation of antibodies against only the optimal epitope.
This systematic and rational approach to antibody discovery opens
up the potential of discovering antibodies to specific regions of
many important “hard targets” that have not been drugged or are
inadequately drugged to date. The RAD platform has produced
multiple antibodies and ADCs that effectively target
disease-associated proteins, including two antibodies that are
currently in Phase I trials (HMBD-001 and HMBD-002) and a recently
out-licensed ADC (HMBD-501) that will enter the clinic in 2024.
About Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics company
discovering and developing transformative biologics for
hard-to-treat diseases. To address key challenges with current
antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is
building a pipeline of next-generation ADCs using its proprietary
antibody discovery and linker/payload platforms. The company has a
pipeline of ADCs in preclinical development and other novel
biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb)
and HMBD-002 (anti-VISTA mAb) in Phase I and a recently
out-licensed ADC (HMBD-501) that will enter the clinic this year.
The Hummingbird Bioscience approach combines computational and
systems biology with wet lab drug discovery in a
multi-disciplinary, collaborative environment spanning initial
discovery through clinical development. The company harnesses this
integrated approach across target identification and patient
selection, enabling the team to increase the efficiency of
translating novel scientific insights while reducing the inherent
risk in drug discovery and development. At Hummingbird Bioscience,
the commitment to rigorous science, teamwork, and intellectual
integrity underpins our passion to accelerate the journey of new
drugs from concept to clinic.
For more information, please
visit www.hummingbirdbioscience.com, and follow Hummingbird
Bioscience on LinkedIn, X (formerly Twitter),
and YouTube.
Contacts:
MediaCrystal
Hoc.ho@hummingbirdbio.commedia@hummingbirdbio.com+65 6979 5580
Investorsinvestors@hummingbirdbio.com